Literature DB >> 3774652

The association of aplasia cutis congenita with therapy of maternal thyroid disease.

R E Kalb, M E Grossman.   

Abstract

Aplasia cutis congenita, the localized absence of skin at birth, usually is an isolated scalp defect. We examined an infant with aplasia cutis congenita associated with maternal Grave's disease and the use of methimazole during pregnancy. This association was reported twice before. It has certain implications with respect to therapy of pregnant hyperthyroid women.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3774652     DOI: 10.1111/j.1525-1470.1986.tb00534.x

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  5 in total

1.  Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy.

Authors:  E Gianetti; L Russo; F Orlandi; L Chiovato; M Giusti; S Benvenga; M Moleti; F Vermiglio; P E Macchia; M Vitale; C Regalbuto; M Centanni; E Martino; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2015-04-04       Impact factor: 4.256

Review 2.  Treatment of Graves' hyperthyroidism with thionamides: a position paper on indications and safety in pregnancy.

Authors:  M Tonacchera; L Chiovato; L Bartalena; A F Cavaliere; P Vitti
Journal:  J Endocrinol Invest       Date:  2019-11-29       Impact factor: 4.256

Review 3.  Neonatal thyroid disorders.

Authors:  A L Ogilvy-Stuart
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-11       Impact factor: 5.747

4.  Aplasia cutis congenita: Two case reports and discussion of the literature.

Authors:  Alexandros Blionas; Dimitrios Giakoumettis; Elias Antoniades; Evangelos Drosos; Andreas Mitsios; Sotirios Plakas; Georgios Sfakianos; Marios S Themistocleous
Journal:  Surg Neurol Int       Date:  2017-11-09

5.  The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves' Disease Patients Through Regulating the Intestinal Microbiome.

Authors:  Zhe Han; Chaoping Cen; Qianying Ou; Yonggui Pan; Jiachao Zhang; Dongxue Huo; Kaining Chen
Journal:  Front Immunol       Date:  2022-01-10       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.